| Frap is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene | None |
| MTOR signaling has a critical role in the pathogenesis of HCC, with evidence for the role of RICTOR in hepato-oncogenesis. | liver, |
| There are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. | ovarian, |
| Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signalling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism and invasion | prostate, |
| AKT-mTOR pathway is a novel component of oncogene induced DNA damage response in immortalized _normal-like_ breast cells and its suppression may contribute to growth arrest and arrest of the breast tumorigenesis | breast, |
| Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. | breast, |
| Data show that hypoxia-inducible factor 1, alpha subunit (HIF-1alpha) is activated via an proto-oncogene protein Akt/mTOR protein signaling pathway in LCC2 and LCC9 breast cancer cells. | breast, |
| Data show that LINC00963 (MetaLnc9) interacted with the glycolytic kinase PGK1 and prevented its ubiquitination in non-small cell lung cancer (NSCLC) cells, leading to activation of the oncogenic AKT/mTOR signaling pathway. | lung, |
| these data demonstrate that an oncogene-specific decoupling of mTOR from AMPK or AKT signaling accounts for alterations of resistance mechanisms and metabolic phenotypes. Indeed the inhibition of mTOR in BRAF(V600E) cells counteracts the metabolic predisposition and demonstrates mTOR as a potential target in BRAF(V600E)-driven colorectal carcinomas. | colorectal, |
| Studies review the oncogenes and tumor suppressors comprising the regulatory network upstream of mTOR, highlight the cancers in which mTOR is activated. | None |
| Studies indicate that mammalian target of rapamycin (mTOR) pathway has a critical role in oncogenesis has made it a potential therapeutic target. | None |
| concluded that LDHB is a downstream target of mTOR that is critical for oncogenic mTOR-mediated tumorigenesis | None |
| This work provides novel insights into the requirements for MYC-induced oncogenesis by showing that mTORC1 activity is necessary to bypass senescence during transformation of B lymphocytes | None |
| beyond the pivotal position of mTOR to relay the oncogenic signals from the upstream phosphatidylinositol 3-kinase/Akt pathway in human cancer, mTOR is capable potentially of playing a direct role in human tumorigenesis if mutated. | None |
| Glut3 is a downstream target of mTORC1, and it is critical for oncogenic mTORC1-mediated aerobic glycolysis and tumorigenesis. | None |
| The schweinfurthin class of compounds as a novel approach to modulate oncogenic mTOR/AKT signaling for cancer treatment. | None |
| establish a non-canonical oncogenic role of mTOR signalling in recruiting pro-tumorigenic myeloid-derived suppressor cells | None |
| The ectopic overexpression of mTOR reverses the inhibition of niclosamide in EBV lytic replication. Similarly, niclosamide inhibits KSHV lytic replication. Thus, we conclude that niclosamide is a promising candidate for chemotherapy against the acute occurrence and transmission of infectious diseases of oncogenic gamma-herpesviruses. | None |
| REVIEW: Oncogenic Roles of the PI3K/AKT/mTOR Axis | None |